Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe.
Authors
de Bono, JChowdhury, S
Feyerabend, S
Elliott, Tony
Grande, E
Melhem-Bertrandt, A
Baron, B
Hirmand, M
Werbrouck, P
Fizazi, K
Affiliation
The Institute of Cancer Research, London, UKIssue Date
2017-08-22
Metadata
Show full item recordAbstract
Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported.Citation
Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe. 2017 Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2017.07.035PubMed ID
28844372Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2017.07.035
Scopus Count
Collections
Related articles
- Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
- Authors: Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ
- Issue date: 2017 Jul
- Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
- Authors: Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators
- Issue date: 2020 Mar
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
- Authors: Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN
- Issue date: 2019 Dec
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
- Authors: Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J
- Issue date: 2015 Aug
- Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
- Authors: Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN
- Issue date: 2015 Jan